CD8A and neoplasm: Interestingly, NKTR-214 preferentially expanded Thy1.1+ tumor-specific CD8 T cells over the endogenous Thy1.2+ CD8 T cells in spleen at day 7 after treatment (Fig. 4e, Supplementary Figs. 6b and 7e).